ASND vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ASND's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow, while the absence of an Altman Z-Score raises concern about long-term solvency. Despite this, the company exhibits strong revenue growth (42.3% YoY) and a robust gross margin (86.82%), supported by a high analyst consensus of 'strong_buy' and a target price of $282.19. The stock trades at a premium valuation (Price/Sales: 19.27, Forward P/E: 17.77), reflecting market confidence in its growth trajectory rather than current profitability. Insider sentiment is neutral (40/100), suggesting cautious optimism, while technical trends remain bearish, indicating short-term weakness.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ASND vs LLY: Head-to-Head Comparison
This page compares Ascendis Pharma A/S (ASND) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.